Board of Directors
Dr Emad Aljahdali
Chairman
- Extensive executive experience and as a leader in Healthcare/Education /R&D Incubators sector
- Fellow of both, the Royal College of Physicians and Surgeons of Canada and the American College of Occupational and Environmental Medicine
- Former Saudi Aramco chief of preventive medicine services
Elie Haddad
Chief Executive Officer
- Private Equity & Venture Capital specialist, Fund raising, Ecosystem development – Biotech and Healthcare expert
- Advisor to the Saudi and other GCC governments and private sector on Biotech Cities development
- Serial entrepreneur
- Former investment banker with total deal value in excess of $16bn
Rawad Rouhana
Independent Non-Executive Board Member
- Former Private Banker
- Involved in Bio City Development Management
- He has more than 10 years of experience as an Investment Banker and Strategy Advisor, working on several major transactions for real estate, transportation companies and financial institutions in Europe and MENA
Investment Management Committee
Dr Emad Aljahdali
- Extensive executive experience and as a leader in Healthcare/Education /R&D Incubators sector
- Fellow of both, the Royal College of Physicians and Surgeons of Canada and the American College of Occupational and Environmental Medicine
- Former Saudi Aramco chief of preventive medicine services
Elie Haddad
- Private Equity & Venture Capital specialist, Fund raising, Ecosystem development – Biotech and Healthcare expert
- Advisor to the Saudi and other GCC governments and private sector on Biotech Cities development
- Serial entrepreneur
- Former investment banker with total deal value in excess of $16bn
Abdullah Sembawa
- More than 13 years of experience in asset & wealth management and advisory
- Currently the Director of Investment at one of the largest tourism and hospitality groups
- He worked on the public equity side, FI, DPM and Funds, in Alistithmar Capital, Al Awwal Capital and Al Khair Capital
Track Record
A Collective Track Record of 100+ Investment Transactions
The founders of Triple Helix Capital have a deep understanding of the healthcare and biotech industries. They have been investing in these sectors for over 25 years, and they have completed over 100 private equity and venture capital transactions. They have a strong network of contacts in the industry, can rely on key Subject Matter Experts, and they have been able to consistently identify promising investment opportunities. They also have a proven track record of helping companies grow and succeed and register exits for their investors.
For example, they worked closely with Gilead Sciences in the past on behalf of a regional family office to help the company develop and launch its new drugs. Gilead Sciences is now a leading pharmaceutical company, and its stock price has increased by over 1,000% since the investment.
In 2012, the founders invested $5m alongside Andreessen Horowitz’s $20 million in Moderna, as part of an SPV backed by Emirati investors. Moderna was a very early-stage company at the time, and it was developing a new type of vaccine technology called messenger RNA (mRNA). The investment was a bet on the potential of mRNA technology, and it paid off handsomely during the COVID-19 pandemic.
In 2015, an investment in Verily was made, Verily is a subsidiary of Alphabet, the parent company of Google. Verily was developing new technologies for the early detection and treatment of diseases. The investment was a bet on the potential of these technologies, and it has also paid off handsomely. In 2022, Verily’s blood test for Alzheimer’s disease was approved by the FDA.
These are just three examples of successful track records in early stage biotech companies from over the past 10 years. Here are some additional details about the founders’ track record:
- They have a 72% success rate with their investments.
- Their investments have generated an average return of 22% per year.
- They have helped over 15 companies achieve successful exits.
- They have been featured in publications such as The Wall Street Journal, Forbes, and BusinessWeek.
